AzTrials
AzTrials

ADHDNCT03955692

The Efficacy of Cathodal tDCS in ADHD

A study testing tDCS in people with ADHD, run by Mahidol University at 1 site in Thailand.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the effectiveness of five sessions of cathodal tDCS over the left DLPFC on inhibitory control/response inhibition in children and adolescents with ADHD. Read more about this study

Who is it for?
Ages 7 to 16 years
Conditions the study is for
ADHD
What is being tested?
tDCS
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
11 participants
Where
1 siteThailand
Study dates
15 Dec 2017to 1 Dec 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children and adolescents aged 7 to 16 years with suspected ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5TM). Diagnostic confirmation will be performed by pediatric neurologist or psychologist.
  • Right-handed
  • Free of any neurological antecedent, unstable medical conditions such as epilepsy; although tDCS is believed to induce very less or no risk of seizure and epileptic seizure have never been reported in tDCS study even in a study with active epilepsy.

Who cannot join

  • Be unable to understand the instruction
  • No clear neurological antecedent history
  • Presence of intracranial metal implantation, cochlea implant, or cardiac pacemaker
  • Motor or perceptual handicap that would prevent using the computer program
  • For patients who under medication, poor-adjusted to their medication, type and dosage of medication is changed less than 4 weeks prior to the start
  • Subjects are participating in the other protocol or receiving alternative treatment such transcranial magnetic stimulation.

Trial locations and contacts

1 site in 1 country.

Thailand1 site
  • Faculty ofPhysical Therapy, Mahidol University

    Salaya, Nakonpathom, 73170

Other trials in Thailand

About this study

Official title: The Efficacy of Cathodal Transcranial Direct Current Stimulation in Children and Adolescents With Attention-deficit Hyperactivity Disorder

The purpose of this study is to investigate the effectiveness of five sessions of cathodal tDCS over the left DLPFC on inhibitory control/response inhibition in children and adolescents with ADHD. Investigators hypothesize that multiple sessions of cathodal tDCS will induce a greater and long-term effect on inhibitory response in children and adolescents with ADHD.

Read the detailed description

Attention-deficit hyperactivity disorder (ADHD) is one of neural development disorder that characterized by a persistent pattern of inattention, impulsivity and hyperactivity. This disorder begins in childhood and often lasts into adulthood. Rates of ADHD diagnosis have been rising in recent years, a prevalence estimates from 3-7% of childhood worldwide. A recent national prevalence shows that 8.1% of Thai primary school-age children are affected by ADHD . Pharmacological treatment used in ADHD is well-established, however, each patient responds to medication differently and treatment in some of them are limited by side effect and abuse of medication.

In the last decade, transcranial direct current stimulation (tDCS) has received a surge of interest in clinical research since it could modulate cortical excitability and induce plasticity in human brain. The device sends a constant low direct current (e.g. 1-2 mA) delivered to the area of interest through the electrodes. This induces shifts in neuronal resting membrane potential changing cortical excitability. Based on the polarity-specific effects, anodal tDCS increases cortical excitability and cathodal tDCS decreases cortical excitability. To change the cortical excitability, tDCS differs from other brain stimulation techniques such as transcranial magnetic stimulation (TMS) in that it does not cause action potentials in cortical neurons, but rather induces shifts in neuronal resting membrane potential. This is considered to induce a lesser or no risk of a seizure. Given its advantages such as painlessness, safety, easiness to use, and low-cost, a number of tDCS studies has been increasing in the last decade particularly in motor rehabilitation and neuropsychiatric disorders such as depression, autism and schizophrenia with a positive and safety reports in adult and pediatric populations. Possible after-effect of tDCS has been also reported in motor and psychological disorders that opens a way to use tDCS as a therapeutic tool.

The most accepted theory of neural basis of ADHD is deficient of inhibitory control resulting in executive dysfunction. Inhibitory control or response inhibition is key feature of self-control and can be defined as ability to inhibit prepotent actions. Several evidences reveal a physiological association between the prefrontal cortex and its subcortical connection with the pathophysiology of ADHD. Neuroimaging studies demonstrate that regions of the right dorso-lateral prefrontal cortex (DLPFC) play a role in the inhibition of motor response. During preforming an inhibitory task that is usually used to evaluate the efficiency of response inhibition such as stop-signal and go/no-go tasks, this area become active in healthy individual, while in ADHD showed hypo-activation compared to control.

Evidences showed that the task performance in stop-signal and go/no-go tasks can be influenced by tDCS application to the DLPFC in healthy subjects. It was recently reported that a single session of cathodal tDCS, using a single session of 1.5 mA for 15 minutes over the left DLPFC improved their ability to inhibit themselves by do not response to no-go stimulus during go/no-go tasks compared to anodal and sham conditions in adolescents with ADHD. It was postulated that the inter-hemispheric inhibition (IHI) between two regions (left and right DLPFC) might play a role in this finding. Based on the possibility that cathodal stimulation decreases excitability and thus IHI drive from the left DLPFC is decreased, facilitating activity of the right DLPFC where is involved in inhibition of motor response as demonstrated by neuroimaging studies. Using a single session of oscillatory tDCS during early sleep, memory consolidation and reaction times in a go/no-go task were improved on the next day in children with ADHD. This is an argument to explore its possible therapeutic effect in long-term use. Five tDCS sessions for five consecutive days was reported to be safe and improves aspect of attention in children and adolescents with ADHD, however, its after-effect in this population is unknown. In patients with depressive disorder, multiple sessions of tDCS over the left DLPFC for five or ten days has been demonstrated to decrease depressive symptoms and lasted for a month. It was reported in patient with depressive disorder that after five days of tDCS sessions on alternative day did not show an improvement, positive results was observed after 10 days. This suggests that a longer observation period is probably required to detect a true tDCS effect.

The use of electrophysiological techniques, especially of event-related potentials (ERP) measured by means of electroencephalography (EEG) allows for analysis of neural change accompanying inhibitory process in the brain. Two ERP components, the no-go N2 and P3 that are the most commonly studied in go/no-go tasks have been linked to response conflict and response inhibition. Studies have reported lower N2 and P3 amplitudes during go/no-go tasks in children and adolescents with ADHD.

To expand current information on tDCS as an emerging treatment for ADHD patients, in this study, investigators will investigate the effectiveness of multiple sessions of cathodal tDCS over the left DLPFC on inhibitory control in children and adolescents with ADHD. tDCS (cathodal/sham) will be applied every day for five consecutive days. Behavioral and neurophysiological parameters using an inhibitory task (go/no-go tasks) and the no-go N2 and P3 ERP components will be measured before tDCS, immediately after 5 sessions of tDCS, one week later, and one month after treatment onset.

Conditions
ADHD
Being tested
tDCS
Medical subject headings
Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tDCSDevice

    Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children

Study groups in NCT03955692
Study groupRoleWhat they receive
Active tDCSActive comparatorCathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will be used for 15 mins for a session.
Receives: Device: tDCS
Sham tDCSSham comparatorCathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will flow continuously only 120 seconds. The electrode will be attached until the end of stimulation even the current flows only at the beginning.
Receives: Device: tDCS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change of accuracy rate

    Accuracy rate from go/no-go tasks

    Measured: Change from baseline to Day 0 after tDCS (T1)

  2. Change of accuracy rate

    Accuracy rate from go/no-go tasks

    Measured: Change from Day 0 to 1 week after tDCS (T2)

  3. Change of accuracy rate

    Accuracy rate from go/no-go tasks

    Measured: Change form 1 week to 1 month after tDCS (T3)

  4. Change in the amplitude of ERP recording

    The amplitude of the ERP components (N2 and P3) in average will be use as outcome measures to evaluate response inhibition.

    Measured: Change from baseline to Day 0 after tDCS (T1)

  5. Change in the amplitude of ERP recording

    The amplitude of the ERP components (N2 and P3) in average will be use as outcome measures to evaluate response inhibition.

    Measured: Change from Day 0 to 1 week after tDCS (T2)

  6. Change in the amplitude of ERP recording

    The amplitude of the ERP components (N2 and P3) in average will be use as outcome measures to evaluate response inhibition.

    Measured: Change form 1 week to 1 month after tDCS (T3)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2019
  2. Study start15 Dec 2017
  3. Primary completion1 Jul 2019
  4. Study completion1 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03955692
Sponsor's protocol ID
MU-IRB 2017/046.2002
Status last verified
Aug 2020
First submitted
16 Nov 2017
Last updated
6 Aug 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Klomjai W, Siripornpanich V, Aneksan B, Vimolratana O, Permpoonputtana K, Tretriluxana J, Thichanpiang P. Effects of cathodal transcranial direct current stimulation on inhibitory and attention control in children and adolescents with attention-deficit hyperactivity disorder: A pilot randomized sham-controlled crossover study. J Psychiatr Res. 2022 Jun;150:130-141. doi: 10.1016/j.jpsychires.2022.02.032. Epub 2022 Mar 2.

    PubMed 35367657

Questions about this trial

What is this clinical trial studying?

A study testing tDCS in people with ADHD, run by Mahidol University at 1 site in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change of accuracy rate (time frame: Change from baseline to Day 0 after tDCS (T1)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03955692, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in